Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425638 | 0.88 | TRPM8 (0.48) | CYP4F2CYP4A11SMN1; SMN2LMNAPKM | |
| SCHEMBL10778842 | 0.86 | PTGS1 (0.51) | SMN1; SMN2LMNAPKMTRPM8L3MBTL1 | |
| SCHEMBL2593722 | 0.85 | PPARG (0.46) | CYP4F2CYP4A11SMN1; SMN2LMNAPKM | |
| SCHEMBL25911838 | 0.85 | SMN1; SMN2 (0.45) | CYP4F2CYP4A11SMN1; SMN2LMNAPKM | |
| SCHEMBL6282888 | 0.84 | CYP4F2 (0.69) | CYP4F2CYP4A11SMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL68340 | 0.84 | PKM (0.60) | CYP4F2CYP4A11SMN1; SMN2LMNAPKM | |
| SCHEMBL7353766 | 0.83 | KMT2A (0.51) | CYP4F2CYP4A11LMNAKMT2AKDM4E | |
| SCHEMBL5153164 | 0.82 | ALDH1A1 (0.50) | LMNAKMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL10981131 | 0.82 | ALDH1A1 (0.49) | SMN1; SMN2LMNAPKMTRPM8KMT2A | |
| SCHEMBL28882208 | 0.82 | ALDH1A1 (0.50) | LMNAKMT2AKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | claimed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | claimed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | claimed |
| CN-112441900-B | Preparation method of 4-felbinac | 浙江中科创越药业有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-117683173-A | Polymer, resist composition, and pattern forming method | 信越化学工业株式会社 | 2024-03-12 | — | — | CN | disclosed |
| CN-116774519-A | Resist material and pattern forming method | 信越化学工业株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-116774520-A | Resist material and pattern forming method | 信越化学工业株式会社 | 2023-09-19 | — | — | CN | disclosed |
| CN-111187235-B | Novel salt compound, chemically amplified resist composition, and pattern forming method | 信越化学工业株式会社 | 2023-06-06 | — | — | CN | disclosed |
| CN-116136645-A | Chemically amplified resist composition and pattern forming method | 信越化学工业株式会社 | 2023-05-19 | — | — | CN | disclosed |
| WO-2022160971-A1 | CONCENTRATE CONTAINING POORLY SOLUBLE DRUG, AND EMULSION PREPARED THEREFROM | 北京德立福瑞医药科技有限公司 | 2022-08-04 | — | — | WO | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-20060111593-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2006-05-25 | — | — | US | disclosed |
| US-7041856-B2 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-09 | — | — | US | disclosed |
| US-20030162950-A1 | Coupling catalyst and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-08-28 | — | — | US | disclosed |
| US-6576628-B1 | Matrix metalloprotease inhibitors; arthritis, corneal ulcers, arteriosclerosis | ROCHE DIAGNOSTICS GMBH (DE) | 2003-06-10 | — | — | US | disclosed |
| EP-1306131-A2 | Cross-Coupling catalyst comprising a cyclic nitrogen ligand and process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-05-02 | — | — | EP | disclosed |
| EP-0141656-B1 | IMPREGNATED CAPACITOR | TORAY INDUSTRIES, INC. (JP) | 1988-06-01 | — | — | EP | disclosed |
| EP-0141656-A1 | Impregnated capacitor | TORAY INDUSTRIES, INC. (JP) | 1985-05-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | CYP4F2 487/4885CYP4A11 800/4885SMN1; SMN2 4452/4885 |
| US-20030162950-A1 | Coupling catalyst and process using the same | NOD1, PYM1, C9 | CYP4F2 932/4885CYP4A11 737/4885SMN1; SMN2 990/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | CYP4F2 549/4885CYP4A11 877/4885SMN1; SMN2 4458/4885 |
| US-20060111593-A1 | Coupling catalyst and process using the same | RPL22, C9, RBM22 | CYP4F2 569/4885CYP4A11 246/4885SMN1; SMN2 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.